biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > $5.25 million

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon Feb 28, 2023 9:45am

125 Views

Post# 35309340

RE:RE:RE:RE:RE:$5.25 million

Yes, poof, I agree. Sell the EGF stuff. Bioasis might get enough to make a couple of payments on the Lind convertible debt.

Remember that the EGF things that are "clinic ready" are not xB3 drugs. CNS xB3 versions of EGF are years away. Sell 'em. Give' em away.

There are bigger, better things to pursue. And Bioasis needs to forget "clinic ready" and NASDAQ for a while. Do something important with xB3, something that begins to make the case that Bioasis is in the same business as Denali.

And put the emphasis on neurotherapeutics, not strictly on rare diseases. That term has lost its value as a corporate strategic descriptor.

jd

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale